BPC-157
Purity: ≥98%
From $52.00
≥98%HPLC Purity
COAIncluded
USAShipped
CJC-1295 (no DAC) Peptide
Modified Growth Hormone Releasing Hormone analog without Drug Affinity Complex. 30-amino acid GHRH analog with enhanced receptor affinity.
$42.00
Quick Facts
| SKU | ACR-CJC1295 |
|---|---|
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | 3367.97 g/mol |
| Sequence | 30-amino acid GHRH analog |
| Purity | ≥98% |
| Physical Form | Lyophilized Powder |
| Storage | Store at -20°C. |
What is CJC-1295 (no DAC)?
CJC-1295 without DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 30-amino acid analog of growth hormone releasing hormone (GHRH). It contains four amino acid substitutions at positions 2, 8, 15, and 27 compared to native GHRH(1-29), specifically designed to improve metabolic stability and resist enzymatic degradation by DPP-IV.
Unlike the DAC (Drug Affinity Complex) variant, this version lacks the maleimidopropionic acid-lysine conjugation that enables albumin binding. This results in a shorter pharmacokinetic profile with more pulsatile receptor activation, which more closely mimics natural GHRH secretion patterns.
For laboratory research use only.
Mechanism of Action
GHRH Receptor Activation
CJC-1295 binds to the growth hormone releasing hormone receptor (GHRHR), a class B G-protein coupled receptor expressed on anterior pituitary somatotroph cells. Receptor activation stimulates Gs-protein coupling, adenylyl cyclase activation, and cAMP production, leading to PKA-mediated GH gene transcription and GH secretion.
Pulsatile vs Sustained Release
The no-DAC variant produces pulsatile GHRH receptor activation due to its shorter half-life (approximately 30 minutes vs 8+ days for the DAC version). This pulsatile pattern is significant because natural GH secretion is pulsatile, and sustained GHRH receptor activation can lead to receptor desensitization.
Synergy with GHS-R1a Agonists
Research has documented synergistic effects when CJC-1295 no DAC is combined with GHS-R1a agonists like Ipamorelin. The GHRH receptor and ghrelin receptor signal through complementary pathways that converge on somatotroph cells, amplifying GH release beyond additive effects.
Frequently Asked Questions
What is CJC-1295 no DAC?
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 30-amino acid GHRH analog with four stabilizing amino acid substitutions. It activates the GHRH receptor on pituitary somatotroph cells. The no-DAC version has a shorter duration than the DAC variant.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC has a Drug Affinity Complex that binds albumin, extending its half-life to 8+ days for sustained GHRH receptor activation. The no-DAC version has a ~30 minute half-life, producing pulsatile stimulation that more closely mimics natural GHRH secretion patterns.
Why combine CJC-1295 no DAC with Ipamorelin?
They target complementary receptors: CJC-1295 activates GHRH receptors while Ipamorelin activates GHS-R1a (ghrelin) receptors. Both receptors are expressed on pituitary somatotroph cells and signal through different but convergent pathways, producing synergistic GH release.
For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.